Post
PhaseV and Quanticate partner to help sponsors run more adaptive trials
PhaseV has partnered with contract research organization (CRO) Quanticate to improve the speed and quality of clinical development programs to …
Exeliom to focus on gastric cancer landscape with immune modulating drug
Paris-based Exeliom Biosciences will focus Phase III efforts of its immune modulating drug EXL01 in gastric cancer if it succeeds …
Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy
US-based Cerevance has secured $47m in Series B-1 extension funding to finance the upcoming Phase III trial for its lead …
Hyundai Bioscience to conduct antiviral trials for Dengue in Brazil
Hyundai Bioscience has announced plans to conduct clinical trials in Brazil for its Niclosamide-based Dengue antiviral. The company’s decision comes after …
FDA approves Freedom Biosciences’s TRD treatment trial
The US Food and Drug Administration (FDA) has approved Freedom Biosciences’s investigational new drug (IND) application for FREE001, enabling the …
Caliway Biopharmaceuticals’ cellulite study meets endpoints
Taiwanese biopharmaceutical company Caliway Biopharmaceuticals has announced that a Phase II trial of its CBL-514 injection lipolysis therapy met all …
Pruvn reports results of trial of serum glutathione supplement
US-based life science research company Pruvn Research has published preliminary findings from a human clinical trial assessing the effects of …
Syphilis, the once near-eliminated STI, is resurging in the US
Syphilis, the sexually transmitted infection (STI) that was once near elimination in the US, is now increasing at an exponential …
PharmaJet’s needle-free delivery system proves effective in published study
A study, published in the Nature Journal, demonstrates that PharmaJet’s needle-free delivery system Tropis significantly boosts immune responses against the …
Podcast #1: Doing Digital Deals in Life Sciences | Corporate Culture
Welcome to the first of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them …
Alkermes begins Phase II trial of ALKS 2680 for narcolepsy type 1
Alkermes has commenced the Vibrance-1 Phase II clinical trial to evaluate ALKS 2680 in patients with narcolepsy type 1 (NT1). ALKS …
CalciMedica enrols last patient for Phase IIb acute pancreatitis trial
CalciMedica has announced the completion of patient enrollment for its Phase IIb CARPO clinical trial, which is evaluating the efficacy …
Gain touts positive Phase I results for Parkinson’s therapy
Gain Therapeutics’ GT-02287 was found to be safe and tolerable in the Phase I trial of the therapy in healthy …
EXO Biologics hopes to gain conditional marketing from Phase I/II BPD trial
EXO Biologics is hoping to receive conditional market approval from the European Medicines Agency (EMA) for its bronchopulmonary dysplasia (BPD) …
Lykos concludes European Phase II study for PTSD
Lykos Therapeutics has completed a European Phase II study (MP18) evaluating midomafetamine (MDMA) capsules for post-traumatic stress disorder (PTSD). MP18 is …